The U.S. Food and Drug Administration (FDA) has recorded the status of product THEOLIXIR under application number ANDA084559. THEOLIXIR is an oral elixir (route: ORAL) marketed by sponsor PANRAY. The product contains the active ingredient THEOPHYLLINE at a strength of 80 mg per 15 mL. According to the FDA filing, the marketing status of THEOLIXIR is listed as discontinued. No reference drug or reference standard is associated with this filing.
Actualizaciones regulatorias25 sept 2026•1 min de lectura
FDA Marks PANRAY's THEOLIXIR Oral Elixir as Discontinued (ANDA084559)
The FDA’s ANDA084559 filing shows PANRAY’s oral elixir THEOLIXIR, containing THEOPHYLLINE 80MG/15ML, is listed as discontinued.
Recopilado por el equipo de PharmaCountry · Fuente: FDA.gov
Calificaciones
(0)
(0)
(0)
(0)
(0)
Más artículos
Ver todos los artículosInvestigación e Informes
Global Finished Dosage Manufacturing Landscape 2026
5 oct 2026
Actualizaciones regulatoriasKorea Korus hit with 1‑month manufacturing suspension over missing post‑marketing safety test
28 sept 2026
AnálisisPharma distributors set delivery cut‑offs ahead of Chuseok holiday (Sep 21‑23)
28 sept 2026
Deja tu valoración